Conference Day Two
8:25 am Chair’s Opening Remarks
Linking Model Data to Better Characterize the Tumour Microenvironment & Predict Translatability
8:30 am Effective Humanized Model Development Strategies to Empower Oncolytic Viral Therapy Research
Synopsis
- Pros and cons of huCD34+ grafted humanized CDX models
- Characterization of complex multi-parametric human tumor microenvironment
- Robustness of humanized model system to correlate the human clinical trial data
9:00 am A Translational Approach to Drug Evaluation: From In Vitro Organoids to Advance In Vivo Models
Synopsis
- Comparative ADC Evaluation Across Four Model Systems: Evaluate drug efficacy through single-mouse in vitro PDXO, MiniPDX, PDX, and clinical MiniPDX models
- Comparison of Available IO models: Evaluation of syngeneic and humanized models available, including clinical considerations
- Translational Relevance for Drug Development: Demonstrate how these models bridge preclinical findings to clinical indications, offering insights into drug efficacy and resistance
9:30 am Leveraging in vitro & in vivo Preclinical PK/PD Data to Bridge the Translational Gap for ADC & CD3 Bispecific Clinical Development
Synopsis
- Bridging preclinical data to clinical predictions, including the use of non-clinical data for efficacious dose predictions and safety mitigations
- Strategies to empower dose predictions of an ADC and a CD3 bi-specific
- Assessing the different model data to be leveraged and understanding the opportunities and challenges with them
10:00 am Morning Break & Networking
Employing the Right Tumor Models to Empower ADC, IO, & Cell Therapy Studies
11:00 am Investigating An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Enhanced Potency & Persistence Against Multiple Oncology Indications
Synopsis
- Exploring a third generation armored allogeneic anti-CD70 CAR gamma delta T cell product
- Demonstrating rapid homing, activation and killing kinetics in preclinical models
- ADI-270 exhibited significant efficacy across multiple solid and hematological tumor models expressing various levels of CD70
11:30 am Mouse Models to Study Mechanisms of Drug Resistance in Immunotherapies & ADCs
Synopsis
- Establishment and validation of in vivo and in vitro trastuzumab deruxtecan (Enhertu)-induced resistant tumor models
- Creation of syngeneic and engineered models of primary and acquired resistance to anti-PD1 therapies (e.g., CT26-PD1-R and B2M-KO models)
- Other humanized and syngeneic mouse models tailored for immune checkpoint inhibitors, ADCs, and combination of therapies
12:00 pm Empowering Cell Therapy Studies by Using Better In Vivo Models
Synopsis
- Uncovering the model selection rationale for cell therapy studies
- Spotlighting key considerations such as antigen expression, TME, and pharmacokinetics in implementing relevant preclinical models
12:30 pm Lunch Break
Emerging Models & Their Applications Across Drug Development
1:30 pm Mastermind Session: Assessing the Range of Tumor Models & Their Applications Across Drug Discovery & Development
Synopsis
Moderated by the Event Chair
- Reflecting on the recent advances in complex in vitro models, PDX and CDX mice and humanized mouse
- How do you effectively select which model to use?
- Defining which models are best for safety, tolerability, or efficacy
2:00 pm SLE Patient PBMC Reconstituted Mouse Model for Lupus Drug Discovery & Development
Synopsis
- Sharing the case study of preclinical model development in autoimmune disease research
- Discussing opportunities and challenges for the development of humanized mouse models of SLE
- Uncovering strategies to repurpose B cell targeting immune therapies for autoimmune disorders